Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Rachman
J
J
Eli Lilly, Basingstoke, UK.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D000077270:Exenatide; D005934:Glucagon / Q000031:analogs & derivatives / Q000502:physiology* / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D010446:Peptide Fragments / Q000502:physiology* / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000502:physiology* / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide